European Pharmaceutical Review

JULY 18, 2022

Some people with haemophilia may also develop inhibitors, antibodies that are an immune response to the clotting factors in replacement therapy that cause the treatment to stop working. Dosing in the Phase III study is expected to start in the fourth quarter of 2022. Novo Nordisk – concizumab and Mim8. compared to 11.8

Immunization 98

Immunization Immunity Hospitals 98

Digital Pharmacist

OCTOBER 24, 2022

Date of Approval: 9/30/2022. Date of Approval: 9/29/2022. Date of Approval: 9/22/2022. Date of Approval: 9/21/2022. Date of Approval: 9/14/2022. Date of Approval: 9/9/2022. Below we will be listing some of the new drug therapy advances and approvals that the FDA had in the month of September.

Adverse Reactions 75

Adverse Reactions Labelling Immunization Pharmacy Management 75

BioPharma Dive

JULY 23, 2024

Peter Lebowitz, who for years led J&J’s oncology R&D, is the CEO of the startup, called Third Arc Bio and launched by Omega Funds in 2022.

Immunization 85

Immunization Immunity 85

PharmaTech

JUNE 10, 2025

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Washington, DC, USA - June 24, 2022: The symbol of the U.S. Kennedy Jr. Press Release.

Vaccines 85

Vaccines Insurance Coverage and Processing Dosage Drug Development 85

Pharmaceutical Technology

SEPTEMBER 13, 2022

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. The post ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers?

Immunization 69

Immunization Immunity Chemotherapy 69

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In August 2022, the MHRA approved Moderna’s adapted vaccine for COVID-19, Spikevax bivalent Original/Omicron as a booster treatment.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

NOVEMBER 11, 2022

Marc Pelletier , Senior Principal Scientist – Translational Immune Oncology, Novartis. Kate Fitzgerald , Professor & Vice Chair, Department of Medicine, Division of Innate Immunity, University of Massachusetts Chan Medical School. The post 4th Inflammasome Therapeutics Summit 2022 appeared first on.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

Express Pharma

MARCH 29, 2023

The statement informed that the company has achieved the following: Closing the micronutrient gap of 642 million vulnerable people in 2022 through the fortification for staple foods, public health initiatives, and emergency relief supplements. The company aims to support 500 million people by 2030.

Immunization 95

Immunization Immunity 95

The Thyroid Pharmacist

DECEMBER 2, 2022

No one is immune to the ups and downs of life – circumstances change, we experience loss, and the ongoing noise around us can become overwhelming. The post Hashimoto’s Success Stories and Gratitude for Healing in 2022 appeared first on Dr. Izabella Wentz, PharmD. For future updates, follow us on Facebook , Instagram and TikTok , too!

Compounding 97

Compounding Immunization Immunity 97

Pharma Mirror

MARCH 7, 2022

While the covid19 pandemic showed us just how important physical health and a robust immune system are, the news of the war is quickly showing us the importance of mental well-being. The post 8 Effective Ways To Enhance Your Health In 2022 appeared first on Pharma Mirror Magazine.

Immunity 52

Immunity Immunization 52

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells.

Immunization 143

Immunization Immunity Drug Development 143

pharmaphorum

DECEMBER 4, 2020

First data from the study is expected by the second quarter of 2022 and all three studies will support a phase 3 pivotal efficacy trial including all main target populations for the Lyme vaccine, starting in 2022. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.

Vaccines 119

Vaccines Immunization Immunity 119

Express Pharma

APRIL 17, 2023

Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialisation of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

Immunity 98

Immunity Immunization Research Laboratories Labelling 98

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). In March 2022, the US Food and Drug Administration approved the IND application for SM17 to treat asthma. In March 2022, the US Food and Drug Administration approved the IND application for SM17 to treat asthma.

Immunization 109

Immunization Immunity Drug Development 109

pharmaphorum

MAY 19, 2022

It codes for an antigen called eOD-GT8 60mer and, in the study, stimulated a targeted B-cell immune response in 97% of vaccine recipients. — Moderna (@moderna_tx) May 18, 2022. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US.

Vaccines 145

Vaccines Immunization Immunity 145

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. Suite 250, Rockville, MD 20850). Creation: Jan.

Immunization 105

Immunization Immunity Chemotherapy Compounding 105

Express Pharma

NOVEMBER 13, 2024

Simi Badyal MSc, Senior Competitive Intelligence Immunology Analyst at GlobalData, comments: “CAR T cell therapies have gained immense traction in recent years within immunology and autoimmune diseases, driven by promising results from the Georg Schett study, first published in 2022.”

Immunity 105

Immunity Immunization 105

Express Pharma

AUGUST 23, 2023

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Vaccines 98

Vaccines Documentation Immunity Immunization 98

BioPharma Dive

APRIL 14, 2025

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it pursued after halting work on a different immune drug in 2022.

Immunity 64

Immunity Immunization 64

European Pharmaceutical Review

AUGUST 16, 2022

The MHRA’s decision is based on data from a clinical trial which showed that a booster dose of the bivalent Moderna vaccine triggers a strong immune response against both Omicron (BA.1) In an exploratory analysis the bivalent vaccine was also found to generate a good immune response against the Omicron sub-variants BA.4

Vaccines 105

Vaccines Immunity Immunization 105

European Pharmaceutical Review

JULY 13, 2023

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

Immunity 98

Immunity Immunization Hospitals 98

Pharmaceutical Technology

SEPTEMBER 14, 2022

Generation of an anti-tumour immune response can lead to complete and durable tumour regression across cancer types, with effector T cells being a critical component. Anti-CD25 monoclonal antibodies (mAbs) were developed as a means of targeting Tregs for antibody-dependent cellular cytotoxicity (ADCC), thereby eradicating this immune subset.

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. In 2022, the drug was approved by the US Food and Drug Administration (FDA) for these patients.

Immunization 97

Immunization Immunity Hospitals Drug Development 97

Pharmaceutical Technology

NOVEMBER 14, 2022

Such developments, including a 2021 approval of AstraZeneca’s Saphnelo (anifrolumab) , prompted The Lancet Rheumatology to posit that 2022 could be a “banner year” for the condition. In lupus, the body’s immune system starts to attack its own cells. MSCs and CAR-Ts for lupus.

Immunization 144

Immunization Immunity 144

European Pharmaceutical Review

SEPTEMBER 26, 2022

At the 2022 European Society for Medical Oncology Congress (ESMO) conference, promising results from a Phase I trial, suggesting that a novel genetically modified (GM) herpes virus eradicated or reduced advanced cancers, were presented.

Immunity 98

Immunity Immunization 98

pharmaphorum

APRIL 23, 2021

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an accelerated review by the EMA. . The post Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon appeared first on.

Labelling 52

Labelling Immunization Immunity 52

pharmaphorum

SEPTEMBER 27, 2022

Seagen’s deal is another endorsement of Lava’s Gammabody platform, which creates drug candidates that target immune cells known as gamma delta or V?9V?2 The biotech said earlier it planned to seek FDA approval to start clinical trials towards the end of 2022. 2 T cells, which have potent tumour-killing activity.

Immunization 111

Immunization Immunity 111

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology.

Mayo Clinic 105

Mayo Clinic Dosage Biosimilars Immunization 105

pharmaphorum

JUNE 21, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform, and is based on a combination of four mRNA-encoded, tumour-associated antigens – NY-ESO-1, MAGE-A3, tyrosinase, and TPTE – that are designed to stimulate an immune response against a cancer.

Vaccines 145

Vaccines Immunization Immunity 145

pharmaphorum

FEBRUARY 9, 2022

Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccines 134

Vaccines Immunization Immunity Labelling 134

Pharmaceutical Technology

APRIL 17, 2023

Prometheus Biosciences uses precision medicine to discover, develop and commercialise new therapeutic and companion diagnostic products to treat immune-mediated diseases. The company will buy all of Prometheus Biosciences’ outstanding shares for $200 a share through a subsidiary. TL1A is implicated in intestinal inflammation and fibrosis.

Immunization 105

Immunization Immunity 105

European Pharmaceutical Review

MAY 4, 2023

According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity.

Immunization 98

Immunization Immunity Chemotherapy 98

pharmaphorum

JULY 5, 2022

T-cell engagers are designed to redirect the immune system’s T-cells to recognise and kill cancer cells and – according to AZ’s head of haematology R&D Anas Younes – TNB-486 given alone or in combination with CD20 drugs like rituximab “could potentially deepen clinical responses and improve patient outcomes.”

Immunization 124

Immunization Immunity 124

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunization 98

Immunization Immunity Chemotherapy 98

LifeProNow

APRIL 11, 2023

Nirsevimabhas been developed to offer newborns and infants direct RSV protection via an antibody to help prevent lower respiratory tract disease (LRTD) caused by RSV.Monoclonal antibodies do not require the activation of the immune system to help offer timely, rapid and direct protection against disease.

Immunization 130

Immunization Immunity 130

FDA Law Blog: Biosimilars

APRIL 30, 2023

Senate Committee on Health, Education, Labor and Pensions (“Senate HELP”) is scheduled to take up legislation that could significantly limit access to the courts and immunize critical FDA decisions from timely judicial review. 1067, which first reared its head in Spring 2022 as an amendment to S.4348, Shumsky — On May 2nd, the U.S.

Immunization 59

Immunization Immunity Biosimilars Labelling 59

BioPharma Dive

JULY 9, 2025

billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive. It’s a way to dismantle a critical barrier to immune and therapeutic access,” he wrote in an email to BioPharma Dive. Other large companies, like Bristol Myers Squibb and Eli Lilly , have entered the field with acquisitions of earlier-stage public biotechs.

Drug Pricing 52

Drug Pricing Compounding Immunization Immunity 52